Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.070
0.00 (0.00%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Cardiol Therapeutics Employees
Cardiol Therapeutics had 18 employees as of December 31, 2024. The number of employees increased by 12 or 200.00% compared to the previous year.
Employees
18
Change
12
Growth
200.00%
Revenue / Employee
n/a
Profits / Employee
-$1,416,160
Market Cap
88.82M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | 12 | 200.00% |
| Dec 31, 2018 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRDL News
- 9 days ago - Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Newsfile Corp
- 24 days ago - Cardiol Therapeutics Announces Year-End 2024 Update on Operations - Newsfile Corp
- 7 weeks ago - Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - Newsfile Corp
- 2 months ago - Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure - Newsfile Corp
- 2 months ago - Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts - Seeking Alpha
- 2 months ago - Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Newsfile Corp
- 4 months ago - PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - GlobeNewsWire
- 5 months ago - Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 - Newsfile Corp